Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127296 · ClinicalTrials.gov registry record · Phase 1
Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00127296 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 60 participants.
The verdict
NCT00127296, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this trial - insulin is dispensed into an empty vial.
Interventions
- DEVICE FlexPen®
- DEVICE vial and syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-07 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127296
The ClinicalTrials.gov registry entry for NCT00127296 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FlexPen® is the first listed.
NCT00127296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00127296 about?
NCT00127296 is a clinical study titled "Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe". This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this tri...
What is the current status of trial NCT00127296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-07. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00127296?
The interventions under investigation include: FlexPen® (DEVICE), vial and syringe (DEVICE).
Who is sponsoring clinical trial NCT00127296?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.